Abstract Objective: To describe the frequency and types of drug-related problems (DRPs) in hospitalised patients, and to identify risk factors for DRPs and the drugs most frequently causing them. Methods: From May to December 2002, 827 patients from six internal medicine and two rheumatology departments in five hospitals in Norway were included in this study. We recorded demographic data, drugs used, relevant medical history, laboratory data and clinical/ pharmacological risk factors, i.e. reduced renal function, reduced liver function, heart failure, diabetes, compliance problems, drugs with a narrow therapeutic index and drug allergy. DRPs were documented after reviewing medical records and participation in multidisciplinary team discussions. An independent quality assessment team retrospectively assessed the DRPs in a randomly selected number of the study population. Results: Of the patients, 81% had DRPs, and an average of 2.1 clinically relevant DRPs was recorded per patient. The DRPs most frequently recorded were dose-related problems (35.1% of the patients) followed by need for laboratory tests (21.6%), non-optimal drugs (21.4%), need for additional drugs (19.7%), unnecessary drugs (16.7%) and medical chart errors (16.3%). The patients used an average of 4.6 drugs at admission. A multivariate analysis showed that the number of drugs at admission and the number of clinical/pharmacological risk factors were both independent risk factors for the occurrence of DRPs, whereas age and gender were not. The drugs most frequently causing a DRP were warfarin, digitoxin and prednisolone, with calculated risk ratios 0.48, 0.42 and 0.26, respectively. The drug groups causing most DRPs were B01A-antithrombotic agents, M01A-non-steroidal anti-inflammatory agents, N02A-opioids and C09A-angiotensin converting enzyme inhibitors, with risk ratios of 0.22, 0.49, 0.21 and 0.35, respectively. Conclusions: The majority of hospitalised patients in our study had DRPs. The number of drugs used and the number of clinical/pharmacological risk factors significantly and independently influenced the risk for DRPs. Procedures for identification of, and intervention on, actual and potential DRPs, along with awareness of drugs carrying a high risk for DRPs, are important elements of drug therapy and may contribute to diminishing drug-related morbidity and mortality.
Introduction
For most diseases, drug therapy will enhance healthrelated quality of life. However, inappropriate use of drugs may be harmful and could evoke new symptoms. Drug therapy is growing more complex, thus making appropriate drug prescribing increasingly challenging. Accordingly, in clinical medicine, a wide range of drugrelated problems (DRPs) may arise. DRPs include costs [1, 2] . A recent study in the US estimated that the cost of treating conditions caused by inappropriate medication was US $177.4 billion in 2000 [3] . Optimisation of drug therapy may, by preventing DRPs, influence health expenses, potentially save lives and enhance each patient's quality of life [4] [5] [6] .
Previous studies have largely addressed DRPs as a cause of hospitalisation [7] . Inappropriate drug use has been studied in the elderly [8] , in ambulatory care [9] and in nursing homes [10] . The definition of DRPs varies considerably, and in many studies only adverse drug reactions (ADRs), which are merely a part of the whole issue of DRPs, have been included. Studies on the prevalence of DRPs in hospitals and a closer characterisation of all DRPs are virtually lacking. Moreover, DRPs have often been addressed through studies on databases. The clinical approach-bedside evaluation of patients' DRPs-has rarely been applied. Thus, the aims of this study were to (1) address all DRPs in all adults, including actual DRPs as well as potential DRPs; that is DRPs which, if left unresolved, may lead to drug-related morbidity and (2) identify risk factors for DRPs and the drugs most frequently causing them.
Materials and methods

Patients and design
A prospective multicentre design was applied. The study was approved by the Regional Committee for Medical Research Ethics. From May to December 2002, experienced clinical pharmacists recorded the drugs used by patients admitted to six departments of internal medicine and two departments of rheumatology in five general hospitals in Norway. Emergency departments were not included. The patients were consecutively included. Re-admission of eligible patients was excluded. The following data were recorded for each patient: age, gender, present complaints, drugs, diagnoses, relevant medical history and results of laboratory tests.
Some specific factors that are assumed to increase the risk of DRPs occurring were recorded. These, which by nature are a composition of pharmacological, clinical and patient-related factors, here called clinical/pharmacological risk factors, were the following: polypharmacy (defined as ‡five drugs at admission), reduced renal function (creatinine clearance below 50 ml/min or serum creatinine above normal range), reduced liver function [aspartate amino transferase (AST) or alanine aminotransferase (ALT) three times above normal values], confirmed diabetes mellitus, cardiac failure, history of allergy or adverse reactions to drugs, assumed noncompliance, use of drugs with a narrow therapeutic index, and other factors that could affect taking the drugs prescribed, including alcohol abuse and problems with swallowing.
Data collection
A standard data recording form was used. The form was designed, tested and found applicable for the participating departments. Clinical pharmacists collected the data from medical charts, medical records, physicians' ward rounds and from the multidisciplinary meetings where each patient was discussed with regard to diagnosis, management and follow-up. DRPs were identified using explicit criteria listed in local and National Therapy Guidelines [11] and the Norwegian Drug Catalogue. These also included lists of clinically important drug-drug interactions and lists of drugs inappropriate to use by patients with renal or liver failure.
DRPs identified before registration but not acted upon were still registered as DRPs. DRPs identified and handled appropriately before the registration were not recorded as DRPs. The identified DRPs were discussed at the multidisciplinary meeting. The participants were physicians, nurses, clinical pharmacists and occasionally other members of the health care team.
Classification of drugs and DRPs
The drugs were classified according to the ATC system [12] . The DRPs were defined according to the definition of Pharmaceutical Care Network in Europe: ''An event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes'', http://www.pcne.org [13] . The classification of DRPs is shown in Table 1 and was compiled according to a modified version of Strand et al. [14] .
For the DRP, drug interaction, a generally accepted grading according to clinical significance was used [15] [16] [17] [18] . Only those graded as important, were included. An One medication may introduce more than one DRP, some of them dependent on each other. For example, a given drug may have caused an interaction, a dose reduction may be needed, and monitoring the drug by laboratory tests may also be required. Thus, three DRPs could be counted. For the patient, however, only one problem exists-the actual drug itself. Therefore, the frequency of DRPs per patient was specified both as a number of medication-DRPs (M-DRPs), a term primarily suited for scientific purposes and as a number of patient-related DRPs (P-DRPs). The latter gives a better description of the number of clinically relevant DRPs. Consequently, the number of M-DRPs are higher than the number of P-DRPs.
Risk factors for occurrence of DRPs and drugs at risk
Information on possible risk factors such as age, gender, number of drugs used at admission, total number of clinical/pharmacological risk factors and type of department were analysed in a multivariate logistic regression model.
In order to identify ''drugs at risk'', we introduced a drug risk ratio for the various drugs and drug groups, this being the number of P-DRPs in relation to number of times the medication was used.
Quality assessment
DRPs discussed at the multidisciplinary meetings were, in most cases, solved there. The meeting itself acted as a body for quality assessment of the DRPs. Furthermore, an independent quality assessment team was appointed, consisting of a professor in clinical pharmacology who is also a specialist in internal medicine, and two specialists in hospital pharmacy with long experience as clinical pharmacists. The team retrospectively assessed the clinical significance of the DRPs registered. Every sixth patient entered into the dataset was selected for this quality assessment. The clinical significance of the DRPs was classified into four groups: extremely important, major, moderate or minor. Extremely important DRPs included those needing interventions to prevent death or severe or irreversible detrimental effects. Major clinical significance was classified as DRPs needing interventions to prevent major or reversible detrimental effects, or lack of therapy in conditions where evidence-based options were available. Moderate clinical significance referred to DRPs where interventions resulted in moderate benefit for the patient. Minor clinical significance was used for DRPs of little clinical importance for the patient, such as minor time adjustment of dosage regimens.
Statistical analysis
The data were analysed in SPSS 11.0 for Windows. Descriptive statistics are shown as means and frequencies with standard errors. A log-linear regression was carried out, with the number of P-DRPs as the dependent variable and possible risk factors as independent variables, to explore the relationship between the occurrence of DRPs and different patient characteristics. A log-transformation was applied to ensure that the dependent variable followed an approximate normal distribution. In addition, the relationship between several of the most common DRPs and the risk factors was studied by means of a logistic regression. Probability values less than 0.05 (P<0.05) were accepted as statistically significant.
Results
Patient characteristics and DRPs
The study included 827 patients, 41.4% male, with a mean age of 70.8 years (15-98 years; Table 2 ). A total of 7,154 drugs were recorded. Of the patients, 81% experienced at least one DRP (range 1-12). Altogether 2,128 M-DRPs and 1,701 P-DRPs were identified. The frequencies of the specific M-DRPs are presented in Table 3 . The drug groups and substances most frequently recorded are shown in Table 4 . Warfarin and prednisolone were the substances most often reported to be involved in DRPs. Warfarin, digitoxin and calcium all had high-risk ratios for DRPs. Other substances less used, but found to have a high-risk ratio, were carbamazepine (0. 
Association between patient factors and DRPs
Age, gender, type of department, number of drugs used at admission and total number of clinical/pharmacological risk factors were analysed to determine whether they could predict the occurrence of DRPs. The number of clinical/pharmacological risk factors and number of drugs at admission were shown to be independent risk factors for the occurrence of DRPs while age and gender were not (Table 5 ). For each additional clinical/pharmacological risk factor, the risk of occurrence of DRPs was increased by 1.14, and each additional drug increased the risk for a DRP by 1.04. Furthermore, the multivariate analysis showed that the risk for DRPs was significantly higher for patients in rheumatology departments than in departments of cardiology, geriatrics or respiratory medicine.
Risk factors predicting the various types of DRPs are shown in Table 6 . The number of drugs at admission was a risk factor for having an unnecessary drug, a nonoptimal drug or a non-optimal dose. For example, for each additional drug the risk for the occurrence of the and Non-optimal drug (32%)
Number and percentage are given in relation to the total of 1,701 P-DRPs and the total of 7,154 drugs used NSAIDs non-steroidal anti-inflammatory drugs a Risk ratio: number of P-DRP/number of times the drug group or the drug was used DRP non-optimal drug was increased by 1.16. The number of clinical/pharmacological risk factors was a risk factor for having an interaction, non-optimal dose, need for laboratory tests or an additional drug. Age was only shown to be an independent risk factor for having an unnecessary drug. Moreover, being a patient at a specific department increased or decreased the risk for the occurrence of specific DRP categories, e.g. patients in rheumatological departments were more prone to need an additional drug than patients in other departments, as shown in Table 6 .
Discussion
The present study showed that a wide variety of DRPs were encountered in the clinical department of general hospitals. In fact, when using the slightly modified version of the well-recognised classification advised by Strand et al. [14] , we found that four-fifths of the patients had DRPs. The magnitude of the problems was illustrated by the finding that the DRP adverse drug reactions, which most often has been specifically investigated in previous studies, contributed to only one-tenth of all DRPs. Some of the DRPs existed at the time of admission to hospital, while others arose during hospital management. In any case, the ultimate result was suboptimal treatment in the short term, exemplified by substandard antibiotic treatment for infections, or longterm, for example, by inadequate use of cardioprotective medication. Increased morbidity is assumed to be the consequence of suboptimal drug therapy in many cases.
To what extent such morbidity was avoided by identification and correction of the DRPs could not be determined in the present study.
To our knowledge, our study is the first to describe all facets of DRPs in clinical departments of general hospitals. The advantage of the prospective design in this study should be emphasised, as many studies on DRPs have been retrospective. Continuous high intensity monitoring enabled us to pick up many DRPs that could otherwise have been overlooked if a retrospective approach had been applied. Other researchers have also shown that more DRPs were identified when high intensity monitoring was used, underscoring that this method is particularly valuable [19, 20] . Furthermore, many studies on DRPs have been performed on large population databases. Use of databases has obvious limitations, perhaps resulting in the recording of ''artificial'' DRPs or the classification of a drug as inappropriate when in fact it is appropriate for a specific patient.
In much of the literature on DRPs, it is not always obvious whether all countable DRPs or the number of clinically relevant DRPs have been registered. Quite often the distinction has not been stated, thus making it difficult to comprehend whether the DRPs reported represent true problems for the patient (P-DRPs) or are medication related (M-DRPs). For the clinicians, information on P-DRP is intuitively easiest to comprehend. However, M-DRP might also be a relevant figure. Our study shows that by applying both of them a more detailed picture of each patient's drug therapy can be presented.
Not only the total number of DRPs, but also the frequencies of the various DRP categories will vary among studies, depending on the methods used. While the DRP adverse drug reactions has traditionally been followed closely, less attention has been paid to other DRPs, of which recognition, nonetheless, should be equally important. In consistence with our study, other researchers have also found high frequencies of inappropriate dosing [7, [21] [22] [23] [24] [25] [26] [27] , inappropriate drugs [9, 28, 29] , need for laboratory tests [30, 31] and need for additional drugs [32] .
Very few studies have used multivariate analysis to identify risk factors related to DRPs [8] . Age, polypharmacy and lists of inappropriate drugs such as Beers list [33] or the medication appropriateness index (MAI) [34] have been suggested as indicators. Generally, the focus has been on elderly patients (>65 years), probably on the assumption that older patients use more drugs and, therefore, may be assumed to have more DRPs. A recent study in hospitalised patients [35] reported that age was not an independent risk factor for ADRs, this being consistent with our finding that age was not a risk factor for total DRPs. More than four drugs (polypharmacy) and co-morbidity (more than four medical problems) have been reported to be significant risk factors for presenting ADRs [36] . Our study confirmed these findings, emphasising that attention should be paid to the number of drugs being used. The number of clinical/pharmacological risk factors appears to be an even stronger predictor for the development of certain DRPs such as interactions, need for laboratory tests, dosage problems and need for additional drugs. The recognition that all age groups are equally at risk for DRPs is important when planning strategies to reduce DRPs.
In the present study, we also estimated the drug risk ratio, this index being the number of DRPs in relation to how often the drug was prescribed. To our knowledge, no other study has given these estimates. We consider the drug risk ratios to be an important and valuable tool in drug use evaluation. A high ratio for an agent indicates that heightened awareness is needed when it is used in clinical practice.
The facts that the patients used an average of about five drugs at admission and that prescribing and discontinuation of drugs during hospitalisation often took place demonstrate the complexity of drug treatment. Under these circumstances, appropriate drug management is challenging. Awareness of the various DRPs and of the predictors of the DRPs should be an important part of high-standard drug therapy.
